Valeant, subsidiary announce early tender results
Valeant Pharmaceuticals announced the results to date of the pending cash tender offers by Valeant and Valeant Pharmaceuticals International, a wholly-owned subsidiary of Valeant, to purchase up to $1.5B aggregate principal amount of their respective outstanding notes listed in the table below, as well as the anticipated early settlement date for the Tender Offers on December 18, 2017. Valeant is the Offeror for the notes issued by it, and VPI is the Offeror for the notes issued by it. Valeant also announced that the maximum aggregate principal amount of 5.375% Senior Notes due 2020 that will be accepted for purchase was increased to $292M, from the previously announced Tender Cap of $200M. All terms and conditions of the Tender Offers remain unchanged as set forth in the Offer to Purchase dated December 4, 2017, as amended by Valeant's press release dated December 4, 2017, announcing the upsize of the Tender Offers, and the related Letter of Transmittal, and capitalized terms used but not defined herein shall have the meaning ascribed to them in the Offer to Purchase. The Tender Offers will expire at 11:59 p.m., New York City time, on January 2, 2018. No tenders will be valid if submitted after the Expiration Date.